木浦勝行

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation

JaLCDOI	10.18926/AMO/54499
フルテキストURL	70_4_243.pdf
著者	Osawa, Masahiro\| Ohashi, Kadoaki\| Kubo, Toshio\| Ichihara, Eiki\| Takata, Saburo\| Takigawa, Nagio\| Takata , Minoru\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
抄録	Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
キーワード	vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2016-08
巻	70巻
号	4号
出版者	Okayama University Medical School
開始ページ	243
終了ページ	253
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27549668
Web of Science KeyUT	000384748600003

Pilot Analysis of Asbestos-induced Diffuse Pleural Thickening with Respiratory Compromise

JaLCDOI	10.18926/AMO/53671
フルテキストURL	69_5_261.pdf
著者	Nojima, Daisuke\| Fujimoto, Nobukazu\| Kato, Katsuya\| Fuchimoto, Yasuko\| Kiura, Katsuyuki\| Kishimoto, Takumi\| Tanimoto, Mitsune\|
抄録	We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
キーワード	asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2015-10
巻	69巻
号	5号
出版者	Okayama University Medical School
開始ページ	261
終了ページ	266
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	26490022
Web of Science KeyUT	000365519600001

HER2異常等の低頻度の分子異常を有する非小細胞肺癌の臨床病理学的特徴を明らかにするための前向き観察研究（HER2-CS Study）と標準化学療法後再発・増悪または標準化学療法不応性のHER2陽性非小細胞肺癌患者を対象としたトラスツズマブエムタンシン（遺伝子組換え）の第2相試験

タイトル（別表記）	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
フルテキストURL	127_127.pdf
著者	木浦勝行\| 堀田勝幸\| 佐藤晃子\| 大橋圭明\| 二宮崇\| 南大輔\| 田端雅弘\| 久保寿夫\| 加藤有加\| 平田泰三\|
キーワード	臨床研究中核病院国立研究開発法人日本医療研究開発機構文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
出版物タイトル	岡山医学会雑誌
発行日	2015-08-03
巻	127巻
号	2号
開始ページ	127
終了ページ	132
ISSN	0030-1558
関連URL	isVersionOf https://doi.org/10.4044/joma.127.127
言語	日本語
著作権者	Copyright (c) 2015 岡山医学会
論文のバージョン	publisher
DOI	10.4044/joma.127.127
NAID	130005096256

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors

著者	Yasugi, Masayuki\| Takigawa, Nagio\| Ochi, Nobuaki\| Ohashi, Kadoaki\| Harada, Daijiro\| Ninomiya, Takashi\| Murakami, Toshi\| Honda, Yoshihiro\| Ichihara, Eiki\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2014-08-15
出版物タイトル	Experimental Cell Research
巻	326巻
号	2号
資料タイプ	学術雑誌論文

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

著者	Ochi, Nobuaki\| Takigawa, Nagio\| Harada, Daijiro\| Yasugi, Masayuki\| Ichihara, Eiki\| Hotta, Katsuyuki\| Tabata, Masahiro\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2014-03-10
出版物タイトル	Experimental Cell Research
巻	322巻
号	1号
資料タイプ	学術雑誌論文

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

著者	Murakami, Toshi\| Takigawa, Nagio\| Ninomiya, Takashi\| Ochi, Nobuaki\| Yasugi, Masaaki\| Honda, Yoshihiro\| Kubo, Toshio\| Ichihara, Eiki\| Hotta, Katsuyuki\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2014-01
出版物タイトル	Lung Cancer
巻	83巻
号	1号
資料タイプ	学術雑誌論文

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model

著者	Hayakawa, Hiromi\| Ichihara, Eiki\| Ohashi, Kadoaki\| Ninomiya, Takashi\| Yasugi, Masayuki\| Takata, Saburo\| Sakai, Katsuya\| Matsumoto, Kunio\| Takigawa, Nagio\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2013-11
出版物タイトル	Cancer Science
巻	104巻
号	11号
資料タイプ	学術雑誌論文

癌告知後の精神症状の治療に難渋したてんかん既往のある癌患者の１例

タイトル（別表記）	Treatment for a non-compliant patient with cancer and epilepsy
フルテキストURL	126_133.pdf
著者	南大輔\| 市原英基\| 岡部伸幸\| 横道直佑\| 高下典子\| 鍛治園誠\| 秋元悠\| 堀圭介\| 松原稔\| 那須淳一郎\| 谷本光音\| 木浦勝行\| 松岡順治\|
抄録	A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
キーワード	てんかん（epilepsy）易怒性（irritability）適応障害（maladjustment）
出版物タイトル	岡山医学会雑誌
発行日	2014-08-01
巻	126巻
号	2号
開始ページ	133
終了ページ	135
ISSN	0030-1558
言語	日本語
著作権者	Copyright (c) 2014 岡山医学会
論文のバージョン	publisher
DOI	10.4044/joma.126.133
NAID	130004685264

Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model

著者	Ninomiya, Takashi\| Takigawa, Nagio\| Ichihara, Eiki\| Ochi, Nobuaki\| Murakami, Toshi\| Honda, Yoshihiro\| Kubo, Toshio\| Minami, Daisuke\| Kudo, Kenichiro\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2013-05
出版物タイトル	Molecular Cancer Therapeutics
巻	12巻
号	5号
資料タイプ	学術雑誌論文

Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency

著者	Takeda, Hiromasa\| Takigawa, Nagio\| Ohashi, Kadoaki\| Minami, Daisuke\| Kataoka, Itaru\| Ichihara, Eiki\| Ochi, Nobuaki\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2013-02-15
出版物タイトル	Experimental Cell Research
巻	319巻
号	4号
資料タイプ	学術雑誌論文

臨床病期Ⅲ期肺非小細胞癌に対する治療戦略

著者	木浦勝行\|
発行日	2013-08-01
出版物タイトル	岡山医学会雑誌
巻	125巻
号	2号
資料タイプ	学術雑誌論文

Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer

著者	Ueno, Tsuyoshi\| Tsukuda, Kazunori\| Toyooka, Shinichi\| Ando, Midori\| Takaoka, Munenori\| Soh, Junichi\| Asano, Hiroaki\| Maki, Yuho\| Muraoka, Takayuki\| Tanaka, Norimitsu\| Shien, Kazuhiko\| Furukawa, Masashi\| Yamatsuji, Tomoki\| Kiura, Katsuyuki\| Naomoto, Yoshio\| Miyoshi, Shinichiro\|
発行日	2012-04
出版物タイトル	Lung Cancer
巻	76巻
号	1号
資料タイプ	学術雑誌論文

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

著者	Shien, Kazuhiko\| Toyooka, Shinichi\| Ichimura, Kouichi\| Soh, Junichi\| Furukawa, Masashi\| Maki, Yuho\| Muraoka, Takayuki\| Tanaka, Norimitsu\| Ueno, Tsuyoshi\| Asano, Hiroaki\| Tsukuda, Kazunori\| Yamane, Masaomi\| Oto, Takahiro\| Kiura, Katsuyuki\| Miyoshi, Shinichiro\|
発行日	2012-07
出版物タイトル	Lung Cancer
巻	77巻
号	1号
資料タイプ	学術雑誌論文

著者	Harada, Daijiro\| Takigawa, Nagio\| Ochi, Nobuaki\| Ninomiya, Takashi\| Yasugi, Masayuki\| Kubo, Toshio\| Takeda, Hiromasa\| Ichihara, Eiki\| Ohashi, Kadoaki\| Takata, Saburo\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2012-10
出版物タイトル	Cancer Science
巻	103巻
号	10号
資料タイプ	学術雑誌論文

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

著者	Kubo, Toshio\| Takigawa, Nagio\| Osawa, Masahiro\| Harada, Daijiro\| Ninomiya, Takashi\| Ochi, Nobuaki\| Ichihara, Eiki\| Yamane, Hiromichi\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2013-01
出版物タイトル	Cancer Science
巻	104巻
号	1号
資料タイプ	学術雑誌論文

Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells

著者	Rai, Kammei\| Takigawa, Nagio\| Ito, Sachio\| Kashihara, Hiromi\| Ichihara, Eiki\| Yasuda, Tatsuji\| Shimizu, Kenji\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
発行日	2011-09
出版物タイトル	Molecular Cancer Therapeutics
巻	10巻
号	9号
資料タイプ	学術雑誌論文

肺癌と分子標的薬

著者	木浦勝行\| 谷本光音\|
発行日	2013-04-01
出版物タイトル	岡山医学会雑誌
巻	125巻
号	1号
資料タイプ	学術雑誌論文

EGFRチロシンキナーゼ阻害薬耐性肺癌細胞に対するmicroRNA-7発現プラスミドのリポソームを用いた導入による克服の検討

著者	頼冠名\| 瀧川奈義夫\| 伊藤佐智夫\| 柏原宏美\| 市原英基\| 保田立二\| 清水憲二\| 谷本光音\| 木浦勝行\|
発行日	2012-12-03
出版物タイトル	岡山医学会雑誌
巻	124巻
号	3号
資料タイプ	学術雑誌論文

Selective Cyclooxygenase-2 Inhibitor Prevents Cisplatin-induced Tumorigenesis in A/J Mice

JaLCDOI	10.18926/AMO/48564
フルテキストURL	66_3_245.pdf
著者	Okada, Toshiaki\| Takigawa, Nagio\| Kishino, Daizo\| Katayama, Hideki\| Kuyama, Shouichi\| Sato, Ken\| Mimoto, Junko\| Ueoka, Hiroshi\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
抄録	Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p＜0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p＜0.01, group 4 vs. group 6).
キーワード	cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2012-06
巻	66巻
号	3号
出版者	Okayama University Medical School
開始ページ	245
終了ページ	251
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	22729105
Web of Science KeyUT	000305669700008

Targeting Angiogenesis in Cancer Therapy

JaLCDOI	10.18926/AMO/47260
フルテキストURL	65_6_353.pdf
著者	Ichihara, Eiki\| Kiura, Katsuyuki\| Tanimoto, Mitsune\|
抄録	Angiogenesis is an essential process in tumor growth. The concept of angiogenesis, when proposed by Folksman in 1971, had a great impact on cancer research and therapy, as the survival and proliferation of cancer depend on angiogenesis, which could be a target of cancer therapy. In subsequent decades, numerous antiangiogenic agents were developed, and some of them have been applied clinically. However, angiogenesis includes a complex and multistep process that has not been sufficiently elucidated. In this review, we focus on signaling pathways related with tumor angiogenesis and several antiangiogenic agents approved by the United States Food and Drug Administration or under investigation.
キーワード	angiogenesis cancer
Amo Type	Review
出版物タイトル	Acta Medica Okayama
発行日	2011-12
巻	65巻
号	6号
出版者	Okayama University Medical School
開始ページ	353
終了ページ	362
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	22189475
Web of Science KeyUT	000298516900001

木浦 勝行